MedTrace Logo

Neural Circuit Effects of Ketamine in Depression

NCT06213324 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-03

No results posted yet for this study

Summary

This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

Conditions

Interventions

DRUG

Ketamine

0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously

DRUG

Placebo

Normal saline delivered intravenously

Sponsors & Collaborators

Principal Investigators

  • James Murrough, MD/PhD · Icahn School of Medicine at Mount Sinai

  • Laurel Morris · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2028-03-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06213324 on ClinicalTrials.gov